share_log

步长制药(603858.SH):控股子公司泸州步长与LANCET就注射用BC001签署《经销和许可协议》

Shandong Buchang Pharmaceuticals (603858.SH): Its subsidiary Lanzhou Buchang signed a Distribution and License Agreement with LANCET for injection BC001.

Gelonghui Finance ·  Aug 14 06:20

Shandong Buchang Pharmaceuticals (603858.SH) announced on August 14 that its controlling subsidiary, Lanzhou Buchang, plans to sign a Distribution and License Agreement with Russian company LANCET. Lanzhou Buchang plans to license LANCET as the holder of the product registration, packaging and quality control for injection BC001 (indicated for cancer treatment, including advanced gastric cancer and gastric-esophageal junction adenocarcinoma) in the Eurasian Economic Union (Russia, Belarus, Kazakhstan, Armenia, and Kyrgyzstan) and Uzbekistan (the "Territory"). LANCET will also operate as the exclusive dealer for the product in the Territory.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment